Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, launched a new assay for quantifying pharmacodynamic markers of radioligand therapies (RLT) in tumors. 
 
Navigate BioPharma’s new image-based test measures the changes in the cancer cells and the tissue after RLT. This assay utilizes multiplex immunofluorescence (mIF) combined with automated quantitative analysis (AQUA) algorithms to precisely measure changes in key protein markers within tumor tissues following radioligand therapy. 
 
These biologically verified markers are incorporated into a single multiplexed fluorescence immunohistochemistry (mFIHC) assay for robust quantitation of the pharmacodynamic activity of RLTs and to gain insights into DNA damage response and mechanism of efficacy from minimal tumor biopsy. This approach offers a comprehensive exploration of a therapy’s impact on cell cycle and DNA damage within a tumor and tumor microenvironment.
 
“Radioligand therapies hold immense promise for targeted cancer treatment,” said Jennifer Bordeaux, PhD, Associate Director of Digital Pathology at Navigate BioPharma Services. “Our new assay provides drug developers with a powerful tool to assess the therapeutic effects of these agents, ultimately accelerating drug development and improving patient outcomes.”